NCT07284017Not yet recruiting
The Impact of Neuronavigation in rTMS for Hemiplegic Stroke Patients.
The Impact of Neuronavigation in Repetitive Transcranial Magnetic Stimulation (rTMS) for Hemiplegic Stroke Patients.
Source: ClinicalTrials.gov · Last updated 16 Dec 2025
Brief summary (registry, in English)
This is a randomized, controlled trial investigating the efficacy and precision of neuronavigation -guided repetitive transcranial magnetic stimulation (rTMS) for motor recovery in patients with subacute stroke hemiparesis. The primary goal is to determine if using neuronavigation to precisely target the unaffected primary motor cortex (M1) improves treatment accuracy, efficiency, and clinical outcomes compared to conventional manual positioning. The study will enroll 30 participants with first-ever stroke onset between 2 weeks and 6 months. Participants will be randomized into two parallel groups: the Experimental Group (neuronavigation-guided rTMS) and the Control Group (conventional positioning rTMS). Both groups will receive the same rTMS parameters: 1 Hz stimulation (low-frequency) over the unaffected M1, 1,200 pulses per session, administered for 10 sessions over 2 consecutive weeks. Primary outcome measures include the change in the Fugl-Meyer Assessment (FMA) Score for the Upper Extremity and the measurement of coil positioning deviation between sessions. Assessments will be conducted at baseline (T0), post-treatment (T1, Week 3), and one month post-treatment (T2, Week 7). This study is funded in part by a research grant from the Metal Industries Research \& Development Centre (MIRDC).
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 30 Nov 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Taichung Veterans General Hospital
- Diseases
- Stroke
- NCT number
- NCT07284017
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 1 Jan 2026 to the primary completion date, 31 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindications to TMS (e.g., metallic implants in head, pacemaker, cochlear implant).
Other illness
- History of epilepsy or seizures.
- Severe cognitive or communication disorders, or inability to give informed consent.
- Unstable medical conditions affecting participation.
- Use of certain medications, including benzodiazepines, antidepressants, muscle relaxants (baclofen, tizanidine), or ongoing botulinum toxin injections for post-stroke spasticity.
Other
- Pregnancy.
- Modified Rankin Scale (mRS) score \>=5 .
Who the study is looking for
- First-ever ischemic or hemorrhagic stroke confirmed by imaging.
- Stroke causing unilateral upper limb weakness (MRC grade \<=3)
- Stroke onset must be between 2 weeks and 6 months prior to enrollment (subacute phase).
- Age between 20 and 85 years old.
- Stable vital signs, clear consciousness, and no cognitive impairment.
- Able to cooperate with assessments and treatment.
- Written informed consent must be signed by the patient or a legal guardian.
Age in the registry: 20 years to 85 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.